Nectar Lifesciences Balance Sheet Health
Financial Health criteria checks 4/6
Nectar Lifesciences has a total shareholder equity of ₹10.8B and total debt of ₹6.3B, which brings its debt-to-equity ratio to 58.4%. Its total assets and total liabilities are ₹21.8B and ₹11.1B respectively. Nectar Lifesciences's EBIT is ₹1.1B making its interest coverage ratio 1.4. It has cash and short-term investments of ₹187.3M.
Key information
58.4%
Debt to equity ratio
₹6.29b
Debt
| Interest coverage ratio | 1.4x |
| Cash | ₹187.35m |
| Equity | ₹10.78b |
| Total liabilities | ₹11.05b |
| Total assets | ₹21.83b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NECLF's short term assets (₹13.1B) exceed its short term liabilities (₹10.0B).
Long Term Liabilities: NECLF's short term assets (₹13.1B) exceed its long term liabilities (₹1.1B).
Debt to Equity History and Analysis
Debt Level: NECLF's net debt to equity ratio (56.6%) is considered high.
Reducing Debt: NECLF's debt to equity ratio has reduced from 78.1% to 58.4% over the past 5 years.
Debt Coverage: NECLF's debt is well covered by operating cash flow (25.2%).
Interest Coverage: NECLF's interest payments on its debt are not well covered by EBIT (1.4x coverage).